Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled time : 15:56 save search
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
Published: 2019-10-31 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 2.86%
H: 6.84%
C: 5.0%
results
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
Published: 2019-11-07 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -11.24%
H: 30.0%
C: 30.0%
results
Aclaris Therapeutics to Present at Upcoming Investor Conferences
Published: 2019-11-12 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -2.21%
H: 2.26%
C: 0.56%
conference presentation therapeutics
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
Published: 2020-01-08 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 0.0%
H: 1.08%
C: 0.54%
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
Published: 2020-01-09 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 22.04%
H: 4.85%
C: -3.96%
results positive results positive trial phase 3 phase 1 phase 2
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Published: 2020-02-10 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.78%
C: -0.78%
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Published: 2020-02-19 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 0.0%
H: 8.53%
C: 3.88%
results
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
Published: 2020-02-25 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 2.19%
H: 2.86%
C: -12.14%
results
Aclaris Therapeutics Secures $11 Million Term Loan Facility
Published: 2020-03-31 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -0.96%
H: 4.85%
C: 0.97%
therapeutics
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
Published: 2020-05-07 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 1.46%
H: 2.88%
C: 2.16%
results
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Published: 2020-05-26 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 2.27%
H: 2.22%
C: -0.74%
conference presentation therapeutics
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
Published: 2020-06-03 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 2.05%
H: 5.37%
C: -3.69%
results trial results trial phase 3 phase 1 phase 2
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
Published: 2020-06-17 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 45.27%
H: 3.26%
C: -19.77%
covid trial syndros
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
Published: 2020-07-07 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 2.82%
H: 1.65%
C: -4.4%
dermatitis drug new drug treatment atopic dermatitis application
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
Published: 2020-08-07 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -2.56%
H: 12.63%
C: 10.53%
results
Aclaris Therapeutics to Present at Upcoming Investor Conferences
Published: 2020-09-01 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -0.43%
H: 3.88%
C: 1.29%
conference presentation therapeutics
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
Published: 2020-10-20 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: 3.1%
H: 1.08%
C: -2.8%
dermatitis trial atopic dermatitis phase 2b
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Published: 2020-11-04 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -1.89%
H: 16.21%
C: 8.52%
results
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
Published: 2020-11-16 (Crawled : 15:56) - globenewswire.com
ACRS | $1.185 -2.87% -2.95% 1.3M
|
Health Technology
|
| O: -1.25%
H: 4.44%
C: 3.49%
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.